The role of allo-HSCT in FLT3-ITD AML in CR1 has long been controversial [22], further complicated by the 2017 European LeukemiaNet (ELN) risk stratification, which determined the risk of relapse based on the allelic ratio (AR) of FLT3-ITD and the NPM1 co-mutation status. This evidence concerns the gene FLT3 and acute myeloid leukemia.